secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001558370-23-004866
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics reports $47.9M cash; Phase 3 uproleselan trial continues to final events in H1 2024
--------------------------------------------------------------------------------

- Cash and equivalents $47.9M at Dec 31, 2022; raised $28.7M net from ATM in Q1 2023.
- R&D expenses fell to $5.9M in Q4 2022 from $12.9M in Q4 2021; full-year R&D $28.4M vs $47.5M.
- DMC recommended Phase 3 uproleselan trial continue after interim utility analysis; final OS events expected H1 2024.
- Appointed Edwin Rock as CMO, Bruce Johnson as CCO, and Chinmaya Rath as CBO in 2022-2023.
- Cash runway projected to fund operations to end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/0001558370-23-004866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837023004866/glyc-20230329x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-004866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer